Scribe just upsized its IPO for gene-edited cholesterol drugs

Signals Inbox·July 26, 2026·Biopharma

Scribe Therapeutics did more than raise $129 million. It became the first gene-editing biotech to price a US IPO in over two years, despite having only one drug in Phase 1. The real bet is that investors are ready to fund CRISPR for common cholesterol problems, not just rare diseases.

Q1What actually happened?

Scribe Therapeutics priced an upsized IPO of 8.58 million shares at $15 each, the top of its range, for $128.7 million in gross proceeds. It had previously planned to sell about 7.1 million shares and expected roughly $96 million in net proceeds. Sanofi also agreed to buy another $7.5 million of stock privately.

Q2Why is this more than another biotech IPO?

Because Scribe is early. Its lead drug, STX-1150, only recently entered Phase 1, while almost every other biotech listing in 2026 arrived with a Phase 2 or later drug. Scribe also became the first gene-editing company to price an IPO since Metagenomi raised $94 million in February 2024.

Q3What is Scribe actually trying to treat?

High LDL cholesterol and related heart risk. STX-1150 is designed to switch off PCSK9 in the liver for years, potentially replacing repeated pills or injections. Unlike permanent DNA editing, Scribe uses epigenetic silencing, which changes how a gene behaves without cutting the underlying DNA sequence.

Q4Why target PCSK9 when drugs already exist?

Because the biology is proven, but long-term use is still messy. Amgen sells the injectable Repatha, Novartis sells the twice-yearly Leqvio, and Merck recently won approval for the first daily oral PCSK9 drug. Scribe is betting that one treatment lasting years could solve the biggest practical problem: people stop taking chronic medicine.

Q5How big is the investor bet?

Big for its stage, but small by 2026 biotech standards. The median biotech IPO this year was above $300 million, more than twice Scribe's haul. That makes the upsizing interesting: investors did not give Scribe a giant late-stage valuation, but they still increased the deal by roughly one-third to back an unusually early gene-editing story.

Q6What does the cash unlock?

Scribe says the money can carry three programs through major data events. About $30 million to $35 million is planned for the Phase 1 STX-1150 study, with first data expected in the first half of 2027. Two earlier programs target LPA and APOC3, other well-known drivers of cardiovascular risk.

Q7So what is the real signal?

Public investors are reopening the door to early gene editing, but only around targets with proven human biology and huge patient markets. Scribe is not asking investors to believe PCSK9 works. It is asking them to believe CRISPR can turn a chronic cholesterol routine into a durable treatment. The 2027 data will decide whether that is a platform shift or just an expensive shortcut.